Corvus Pharmaceuticals (CRVS) Equity Ratio (2022 - 2025)
Corvus Pharmaceuticals (CRVS) has 4 years of Equity Ratio data on record, last reported at 0.89 in Q3 2025.
- For Q3 2025, Equity Ratio rose 322.69% year-over-year to 0.89; the TTM value through Sep 2025 reached 0.89, up 322.69%, while the annual FY2024 figure was 0.47, 44.34% down from the prior year.
- Equity Ratio reached 0.89 in Q3 2025 per CRVS's latest filing, down from 0.9 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.9 in Q2 2025 and bottomed at 0.21 in Q3 2024.
- Average Equity Ratio over 4 years is 0.78, with a median of 0.84 recorded in 2023.
- Peak YoY movement for Equity Ratio: crashed 75.26% in 2024, then soared 322.69% in 2025.
- A 4-year view of Equity Ratio shows it stood at 0.82 in 2022, then rose by 3.27% to 0.85 in 2023, then tumbled by 44.34% to 0.47 in 2024, then soared by 88.69% to 0.89 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.89 in Q3 2025, 0.9 in Q2 2025, and 0.83 in Q1 2025.